Redox-Sensitive Hydroxyethyl Starch-Doxorubicin Conjugate for Tumor Targeted Drug Delivery

ACS Applied Materials and Interfaces

Volumn 8, Issue 45, 2016, Pages 30833-30844

  Hu, Hang ^a   Li, Yihui ^a   Zhou, Qing ^a   Ao, Yanxiao ^a   Yu, Chan ^a   Wan, Ying ^a   Xu, Huibi ^a   Li, Zifu ^a,b   Yang, Xiangliang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan Institute of Biotechnology   (China)

Author keywords

chemotherapy; conjugate; doxorubicin; hydroxyethyl starch; redox sensitive; tumor targeted drug delivery

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG PRODUCTS; ENZYME ACTIVITY; TUMORS;

CONJUGATE; DOXORUBICIN; HYDROXYETHYL STARCHES; REDOX SENSITIVES; TUMOR-TARGETED DRUG DELIVERIES;

STARCH;

DOXORUBICIN; STARCH;

CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; NEOPLASM; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; STARCH;

EID: 84995922909     PISSN: 19448244     EISSN: 19448252     Source Type: Journal    
DOI: 10.1021/acsami.6b11932     Document Type: Article

References (63)

1. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev. 2004, 56 ( 56 ) 185-229 10.1124/pr.56.2.6
2. Abo-Salem, O. M. The Protective Effect of Aminoguanidine on Doxorubicin-Induced Nephropathy in Rats J. Biochem. Mol. Toxicol. 2012, 26 ( 1 ) 1-9 10.1002/jbt.20422
3. Yilmaz, S.; Atessahin, A.; Sahna, E.; Karahan, I.; Ozer, S. Protective Effect of Lycopene on Adriamycin-Induced Cardiotoxicity and Nephrotoxicity Toxicology 2006, 218 ( 2-3 ) 164-171 10.1016/j.tox.2005.10.015
4. Duncan, R.; Vicent, M. J. Do HPMA Copolymer Conjugates Have a Future as Clinically Useful Nanomedicines? A Critical Overview of Current Status and Future Opportunities Adv. Drug Delivery Rev. 2010, 62 ( 2 ) 272-282 10.1016/j.addr.2009.12.005
5. Kataoka, K.; Matsumoto, T.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Fukushima, S.; Okamoto, K.; Kwon, G. S. Doxorubicin-Loaded Poly(ethylene glycol)-Poly(β-benzyl-L-aspartate) Copolymer Micelles: Their Pharmaceutical Characteristics and Biological Significance J. Controlled Release 2000, 64 ( 1-3 ) 143-153 10.1016/S0168-3659(99)00133-9
6. Lu, D.; Wen, X.; Liang, J.; Gu, Z.; Zhang, X.; Fan, Y. A pH-Sensitive Nano Drug Delivery System Derived from Pullulan/Doxorubicin Conjugate J. Biomed. Mater. Res., Part B 2009, 89B ( 1 ) 177-183 10.1002/jbm.b.31203
7. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M. Phase I Clinical Trial and Pharmacokinetic Evaluation of NK911, a Micelle-Encapsulated Doxorubicin Br. J. Cancer 2004, 91 ( 10 ) 1775-1781 10.1038/sj.bjc.6602204
8. Minko, T.; Kopeckova, P.; Kopecek, J. Efficacy of the Chemotherapeutic Action of HPMA Copolymer-Bound Doxorubicin in a Solid Tumor Model of Ovarian Carcinoma Int. J. Cancer 2000, 86 ( 1 ) 108-117 10.1002/(SICI)1097-0215(20000401)86:1<108::AID-IJC17>3.0.CO;2-8
9. Upadhyay, K. K.; Bhatt, A. N.; Mishra, A. K.; Dwarakanath, B. S.; Jain, S.; Schatz, C.; Le Meins, J.-F.; Farooque, A.; Chandraiah, G.; Jain, A. K.; Misra, A.; Lecommandoux, S. The Intracellular Drug Delivery and Anti Tumor Activity of Doxorubicin Loaded Poly(γ-benzyl-glutamate)-b-hyaluronan Polymersomes Biomaterials 2010, 31 ( 10 ) 2882-2892 10.1016/j.biomaterials.2009.12.043
10. Goodarzi, N.; Varshochian, R.; Kamalinia, G.; Atyabi, F.; Dinarvand, R. A Review of Polysaccharide Cytotoxic Drug Conjugates for Cancer Therapy Carbohydr. Polym. 2013, 92 ( 2 ) 1280-1293 10.1016/j.carbpol.2012.10.036
11. Cai, S.; Thati, S.; Bagby, T. R.; Diab, H. M.; Davies, N. M.; Cohen, M. S.; Ml, F. Localized Doxorubicin Chemotherapy with a Biopolymeric Nanocarrier Improves Survival and Reduces Toxicity in Xenografts of Human Breast Cancer J. Controlled Release 2010, 146 ( 2 ) 212-218 10.1016/j.jconrel.2010.04.006
12. Danhauser-Riedl, S.; Hausmann, E.; Schick, H. D.; Bender, R.; Dietzfelbinger, H.; Rastetter, J.; Hanauske, A. R. Phase I Clinical and Pharmacokinetic Trial of Dextran Conjugated Doxorubicin (AD-70, DOX-OXD) Invest. New Drugs 1993, 11 ( 2-3 ) 187-195 10.1007/BF00874153
13. Li, H.; Bian, S.; Huang, Y.; Liang, J.; Fan, Y.; Zhang, X. High Drug Loading pH-Sensitive Pullulan-DOX Conjugate Nanoparticles for Hepatic Targeting J. Biomed. Mater. Res., Part A 2014, 102 ( 1 ) 150-159 (10). 10.1002/jbm.a.34680
14. Parisa, Y.; Fatemeh, A.; Ebrahim, V. F.; Mousavi, A. A.; Rassoul, D. Targeted Delivery of Doxorubicin-Utilizing Chitosan Nanoparticles Surface-Functionalized with Anti-Her2 Trastuzumab Int. J. Nanomed. 2011, 6 ( 6 ) 1977-1990 10.2147/IJN.S21523
15. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs Cancer Res. 1986, 46, 6387-6392
16. Li, G.; Yan, L.; Tang, Y.; Yu, Z.; Yan, Z.; Tian, Y.; Hui, X.; Cai, C.; Xing, T. Hydroxyethyl Starch Conjugates for Improving the Stability, Pharmacokinetic Behavior and Antitumor Activity of 10-Hydroxy Camptothecin Int. J. Pharm. 2014, 471 ( 1-2 ) 234-244 10.1016/j.ijpharm.2014.05.038
17. Venditto, V. J.; Szoka, F. C., Jr Cancer Nanomedicines: So Many Papers and So Few Drugs! Adv. Drug Delivery Rev. 2013, 65 ( 1 ) 80-88 10.1016/j.addr.2012.09.038
18. Duncan, R. Polymer Conjugates as Anticancer Nanomedicines Nat. Rev. Cancer 2006, 6 ( 6 ) 688-701 10.1038/nrc1958
19. Haag, R.; Kratz, F. Polymer Therapeutics: Concepts and Applications Angew. Chem., Int. Ed. 2006, 45 ( 8 ) 1198-1215 10.1002/anie.200502113
20. Lee, S. Y.; Kim, S.; Tyler, J. Y.; Park, K.; Cheng, J. X. Blood-Stable, Tumor-Adaptable Disulfide Bonded mPEG-(Cys)4-PDLLA Micelles for Chemotherapy Biomaterials 2013, 34 ( 2 ) 552-561 10.1016/j.biomaterials.2012.09.065
21. Meng, F.; Hennink, W. E.; Zhong, Z. Reduction-Sensitive Polymers and Bioconjugates for Biomedical Applications Biomaterials 2009, 30 ( 12 ) 2180-2198 10.1016/j.biomaterials.2009.01.026
22. Cheng, R.; Feng, F.; Meng, F.; Deng, C.; Feijen, J.; Zhong, Z. Glutathione-Responsive Nano-Vehicles as a Promising Platform for Targeted Intracellular Drug and Gene Delivery J. Controlled Release 2011, 152 ( 1 ) 2-12 10.1016/j.jconrel.2011.01.030
23. Kuppusamy, P.; Li, H.; Ilangovan, G.; Cardounel, A. J.; Zweier, J. L.; Yamada, K.; Krishna, M. C.; Mitchell, J. B. Noninvasive Imaging of Tumor Redox Status and Its Modification by Tissue Glutathione Levels Cancer Res. 2002, 62, 307-312
24. Lv, S.; Tang, Z.; Zhang, D.; Song, W.; Li, M.; Jian, L.; Liu, H.; Chen, X. Well-Defined Polymer-Drug Conjugate Engineered with Redox and pH-Sensitive Release Mechanism for Efficient Delivery of Paclitaxel J. Controlled Release 2014, 194 ( 12 ) 220-227 10.1016/j.jconrel.2014.09.009
25. Wang, Y.; Lv, S.; Deng, M.; Tang, Z.; Chen, X. A Charge-Conversional Intracellular-Activated Polymeric Prodrug for Tumor Therapy Polym. Chem. 2016, 7 ( 12 ) 2253-2263 10.1039/C5PY01618E
26. Yin, T.; Wang, J.; Yin, L.; Shen, L.; Zhou, J.; Huo, M. Redox-Sensitive Hyaluronic Acid-Paclitaxel Conjugate Micelles with High Physical Drug Loading for Efficient Tumor Therapy Polym. Chem. 2015, 6 ( 46 ) 8047-8059 10.1039/C5PY01355K
27. Zhang, Q.; He, J.; Zhang, M.; Ni, P. A Polyphosphoester-Conjugated Camptothecin Prodrug with Disulfide Linkage for Potent Reduction-Triggered Drug Delivery J. Mater. Chem. B 2015, 3 ( 24 ) 4922-4932 10.1039/C5TB00623F
28. Liu, P.; Shi, B.; Yue, C.; Gao, G.; Li, P.; Yi, H.; Li, M.; Wang, B.; Ma, Y.; Cai, L. Dextran-Based Redox-Responsive Doxorubicin Prodrug Micelles for Overcoming Multidrug Resistance Polym. Chem. 2013, 4 ( 24 ) 5793-5799 10.1039/c3py00830d
29. Su, Y.; Hu, Y.; Du, Y.; Huang, X.; He, J.; You, J.; Yuan, H.; Hu, F. Redox-Responsive Polymer-Drug Conjugates Based on Doxorubicin and Chitosan Oligosaccharide-g-stearic Acid for Cancer Therapy Mol. Pharmaceutics 2015, 12 ( 4 ) 1193-1202 10.1021/mp500710x
30. Hershenson, H.; Brake, J. M.; Roberts, M. Starch Plasma Expanders and Process of Preparation, 1970.
31. Westphal, M.; James, M. F. M.; Kozeklangenecker, S.; Stocker, R.; Guidet, B.; Aken, H. V. Hydroxyethyl Starches Different Products - Different Effects Anesthesiology 2009, 111 ( 1 ) 187-202 10.1097/ALN.0b013e3181a7ec82
32. Jungheinrich, D. C.; Neff, T. A. Pharmacokinetics of Hydroxyethyl Starch Clin. Pharmacokinet. 2005, 44 ( 7 ) 681-699 10.2165/00003088-200544070-00002
33. Noga, M.; Edinger, D.; Kläger, R.; Wegner, S. V.; Spatz, J. P.; Wagner, E.; Winter, G.; Besheer, A. The Effect of Molar Mass and Degree of Hydroxyethylation on the Controlled Shielding and Deshielding of Hydroxyethyl Starch-Coated Polyplexes Biomaterials 2013, 34 ( 10 ) 2530-2538 10.1016/j.biomaterials.2012.12.025
34. Noga, M.; Edinger, D.; Rödl, W.; Wagner, E.; Winter, G.; Besheer, A. Controlled Shielding and Deshielding of Gene Delivery Polyplexes Using Hydroxyethyl Starch (HES) and Alpha-Amylase J. Controlled Release 2012, 159 ( 1 ) 92-103 10.1016/j.jconrel.2012.01.006
35. Treib, J.; Haass, A.; Pindur, G.; Grauer, M. T.; Wenzel, E.; Schimrigk, K. All Medium Starches are not the Same: Influence of the Degree of Hydroxyethyl Substitution of Hydroxyethyl Starch on Plasma Volume, Hemorheologic Conditions, and Coagulation Transfusion (Malden, MA, U. S.) 1996, 36 ( 5 ) 450-455 10.1046/j.1537-2995.1996.36596282590.x
36. Treib, J.; Haass, A.; Pindur, G.; Seyfert, U. T.; Treib, W.; Grauer, M. T.; Jung, F.; Wenzel, E.; Schimrigk, K. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 Hydroxyethylation Ratio of Hydroxyethyl Starch (HES) on Hemorheology, Coagulation and Elimination Kinetics Thromb. Haemostasis 1995, 74, 1452-1456
37. Weidhase, R.; Faude, K.; Weidhase, R. Hydroxyethyl Starch--an Interim Report Anaesthesiol. Reanim. 1998, 23, 4-14
38. Boldt, J.; Haisch, G.; Suttner, S.; Kumle, B.; Schellhaass, A. Effects of a New Modified, Balanced Hydroxyethyl Starch Preparation (Hextend) on Measures of Coagulation Br. J. Anaesth. 2002, 89 ( 5 ) 722-728 10.1093/bja/aef242
39. Kraft, D.; Sirtl, C.; Laubenthal, H.; Scheiner, O.; Parth, E.; Dieterich, H. J.; Széfalusi, Z.; Trampisch, H. J.; Gerlach, E.; Peter, K. No Evidence for the Existence of Preformed Antibodies against Hydroxyethyl Starch in Man Eur. Surg. Res. 1992, 24 ( 3 ) 138-142 10.1159/000129200
40. Treib, J.; Baron, J. F. Hydroxethyl Starch: Effects on Hemostasis Ann. Fr. Anesth. Reanim. 1998, 17 ( 1 ) 72-81 10.1016/S0750-7658(97)80189-X
41. Li, D.; Ding, J.; Zhuang, X.; Chen, L.; Chen, X. Drug Binding Rate Regulates the Properties of Polysaccharide Prodrugs J. Mater. Chem. B 2016, 4 ( 30 ) 5167-5177 10.1039/C6TB00991C
42. Luo, Q.; Wang, P.; Miao, Y.; He, H.; Tang, X. A Novel 5-Fluorouracil Prodrug Using Hydroxyethyl Starch as a Macromolecular Carrier for Sustained Release Carbohydr. Polym. 2012, 87 ( 4 ) 2642-2647 10.1016/j.carbpol.2011.11.039
43. Zhu, Y.; Yao, X.; Chen, X.; Chen, L. pH-Sensitive Hydroxyethyl Starch-Doxorubicin Conjugates as Antitumor Prodrugs with Enhanced Anticancer Efficacy J. Appl. Polym. Sci. 2015, 132 ( 45 ) 42778 10.1002/app.42778
44. Dong, L.; Xia, S.; Wu, K.; Huang, Z.; Chen, H.; Chen, J.; Zhang, J. A pH/Enzyme-Responsive Tumor-Specific Delivery System for Doxorubicin Biomaterials 2010, 31 ( 24 ) 6309-6316 10.1016/j.biomaterials.2010.04.049
45. Kobayashi, H.; Choyke, P. L. Target-Cancer-Cell-Specific Activatable Fluorescence Imaging Probes: Rational Design and in Vivo Applications Acc. Chem. Res. 2011, 44 ( 44 ) 83-90 10.1021/ar1000633
46. Song, Q.; Wang, X.; Wang, Y.; Liang, Y.; Zhou, Y.; Song, X.; He, B.; Zhang, H.; Dai, W.; Wang, X.; Zhang, Q. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy Mol. Pharmaceutics 2016, 13 ( 1 ) 190-201 10.1021/acs.molpharmaceut.5b00631
47. Hoffmann, S.; Caysa, H.; Kuntsche, J.; Kreideweiß, P.; Leimert, A.; Mueller, T.; Mäder, K. Carbohydrate Plasma Expanders for Passive Tumor Targeting: in Vitro and in Vivo Studies Carbohydr. Polym. 2013, 95 ( 1 ) 404-413 10.1016/j.carbpol.2013.03.033
48. Chuan, X.; Qin, S.; Lin, J.; Chen, X.; Hua, Z.; Dai, W.; Bing, H.; Wang, X.; Qiang, Z. Novel Free-Paclitaxel-Loaded Redox-Responsive Nanoparticles Based on a Disulfide-Linked Poly(ethylene glycol)-Drug Conjugate for Intracellular Drug Delivery: Synthesis, Characterization, and Antitumor Activity in Vitro and in Vivo Mol. Pharmaceutics 2014, 11 ( 10 ) 3656-3670 10.1021/mp500399j
49. Gou, P.; Liu, W.; Mao, W.; Tang, J.; Shen, Y.; Sui, M. Self-Assembling Doxorubicin Prodrug Forming Nanoparticles for Cancer Chemotherapy: Synthesis and Anticancer Study in Vitro and in Vivo J. Mater. Chem. B 2013, 1 ( 3 ) 284-292 10.1039/C2TB00004K
50. Liu, H.; Qiao, C.; Yang, J.; Weng, J.; Zhang, X. Self-Assembling Doxorubicin-Prodrug Nanoparticles as siRNA Drug Delivery System for Cancer Treatment: in Vitro and in Vivo J. Mater. Chem. B 2014, 2 ( 35 ) 5910-5924 10.1039/C4TB00814F
51. Koo, A. N.; Lee, H. J.; Kim, S. E.; Chang, J. H.; Park, C.; Kim, C.; Park, J. H.; Lee, S. C. Disulfide-Cross-Linked PEG-Poly(amino acid)s Copolymer Micelles for Glutathione-Mediated Intracellular Drug Delivery Chem. Commun. 2008, 48 ( 48 ) 6570-6572 10.1039/b815918a
52. Li, M.; Tang, Z.; Lv, S.; Song, W.; Hong, H.; Jing, X.; Zhang, Y.; Chen, X. Cisplatin Crosslinked pH-Sensitive Nanoparticles for Efficient Delivery of Doxorubicin Biomaterials 2014, 35 ( 12 ) 3851-3864 10.1016/j.biomaterials.2014.01.018
53. Zhu, Y.; Jian, Z.; Meng, F.; Chao, D.; Ru, C.; Feijen, J.; Zhong, Z. cRGD-Functionalized Reduction-Sensitive Shell-Sheddable Biodegradable Micelles Mediate Enhanced Doxorubicin Delivery to Human Glioma Xenografts in Vivo J. Controlled Release 2016, 233, 29-38 10.1016/j.jconrel.2016.05.014
54. Brülisauer, L.; Gauthier, M. A.; Leroux, J. C. Disulfide-Containing Parenteral Delivery Systems and Their Redox-Biological Fate J. Controlled Release 2014, 195, 147-154 10.1016/j.jconrel.2014.06.012
55. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique Features of Tumor Blood Vessels for Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect Adv. Drug Delivery Rev. 2011, 63 ( 3 ) 136-151 10.1016/j.addr.2010.04.009
56. Cao, X.; Luo, J.; Gong, T.; Zhang, Z. R.; Sun, X.; Fu, Y. Coencapsulated Doxorubicin and Bromotetrandrine Lipid Nanoemulsions in Reversing Multidrug Resistance in Breast Cancer in Vitro and in Vivo Mol. Pharmaceutics 2015, 12 ( 1 ) 274-286 10.1021/mp500637b
57. Hao, Y.; Huang, Y. X.; He, Y. Q.; Peng, J. R.; Chen, L. J.; Hu, X.; Qian, Z. Y. The Evaluation of Cellular Uptake Efficiency and Tumor-Targeting Ability of MPEG-PDLLA Micelles: Effect of Particle Size RSC Adv. 2016, 6 ( 17 ) 13698-13709 10.1039/C5RA26563K
58. Hue, J. J.; Lee, H.-J.; Jon, S.; Nam, S. Y.; Yun, Y. W.; Kim, J.-S.; Lee, B. J. Distribution and Accumulation of Cy5.5-Labeled Thermally Cross-Linked Superparamagnetic Iron Oxide Nanoparticles in the Tissues of ICR Mice J. Vet. Sci. 2013, 14 ( 4 ) 473-479 10.4142/jvs.2013.14.4.473
59. August, D. A.; Halter, S.; Brenner, D. E. Effect of Sublethal Liver Injury on Doxorubicin Metabolism Clin. Cancer Res. 1995, 1, 351-358
60. Brenner, D. E.; Anthony, L. B.; Halter, S.; Harris, N. L.; Collins, J. C.; Hande, K. R. Effect of Allyl Alcohol-Induced Sublethal Hepatic Damage upon Doxorubicin Metabolism and Toxicity in the Rabbit Cancer Res. 1987, 47, 3259-3265
61. Sturgill, M. G.; August, D. A.; Brenner, D. E. Hepatic Enzyme Induction with Phenobarbital and Doxorubicin Metabolism and Myelotoxicity in the Rabbit Cancer Invest. 2000, 18 ( 3 ) 197-205 10.3109/07357900009031824
62. Du, C.; Deng, D.; Shan, L.; Wan, S.; Cao, J.; Tian, J.; Achilefu, S.; Gu, Y. A pH-Sensitive Doxorubicin Prodrug Based on Folate-Conjugated BSA for Tumor-Targeted Drug Delivery Biomaterials 2013, 34 ( 12 ) 3087-3097 10.1016/j.biomaterials.2013.01.041
63. Kaminskas, L. M.; Mcleod, V. M.; Kelly, B. D.; Sberna, G.; Boyd, B. J.; Williamson, M.; Owen, D. J.; Porter, C. J. H. A Comparison of Changes to Doxorubicin Pharmacokinetics, Antitumor Activity, and Toxicity Mediated by PEGylated Dendrimer and PEGylated Liposome Drug Delivery Systems Nanomedicine (N. Y., NY, U. S.) 2012, 8 ( 1 ) 103-111 10.1016/j.nano.2011.05.013